| P2093 | author name string | Alice B Gottlieb | |
| | Paul F Lizzul | |
| | Caroline A Chang | |
| P2860 | cites work | Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis | Q24673687 |
| | Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | Q28202251 |
| | Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis | Q28744054 |
| | Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. | Q31034753 |
| | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors | Q31038425 |
| | Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial | Q31096607 |
| | Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) | Q31169591 |
| | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy | Q33509240 |
| | Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies | Q33623219 |
| | Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature | Q34113718 |
| | Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 |
| | Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines | Q34530618 |
| | Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial | Q34551162 |
| | Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. | Q34583765 |
| | Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study | Q34700921 |
| | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics | Q34771528 |
| | Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure | Q34930633 |
| | The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. | Q35036985 |
| | Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis | Q35086458 |
| | Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial | Q35555905 |
| | Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Q35579437 |
| | A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis | Q71808895 |
| | Psoriasis | Q73245623 |
| | Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study | Q73350638 |
| | Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis | Q74242371 |
| | Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial | Q74265787 |
| | Comparison of disability and quality of life in rheumatoid and psoriatic arthritis | Q74385099 |
| | Clinical and genetic aspects of psoriatic arthritis "sine psoriasis" | Q75248220 |
| | METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS | Q76860899 |
| | Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 |
| | Etanercept as monotherapy in patients with psoriasis | Q79308562 |
| | Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices | Q79340455 |
| | Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort | Q80214315 |
| | Outcome measures in psoriatic arthritis | Q80261276 |
| | Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression | Q80330608 |
| | Efficacy of etanercept in psoriatic patients previously treated with infliximab | Q80577261 |
| | Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2 | Q80707053 |
| | Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept | Q81074693 |
| | Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study | Q81245429 |
| | Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial | Q81300604 |
| | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial | Q81354813 |
| | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) | Q81629371 |
| | Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper | Q81722254 |
| | Autoantibody production in patients treated with anti-TNF-alpha | Q84238512 |
| | Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis | Q84357870 |
| | Psoriatic arthritis sine psoriasis | Q84365730 |
| | Mortality in Psoriatic Arthritis – A Single-center Study from the UK | Q84651042 |
| | Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis | Q35953268 |
| | Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis | Q36030664 |
| | Psoriatic arthritis and psoriasis: need for a multidisciplinary approach | Q36131177 |
| | Psychologic factors in psoriasis: consequences, mechanisms, and interventions. | Q36236256 |
| | Consensus on a core set of domains for psoriatic arthritis | Q36810192 |
| | Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience | Q37005269 |
| | Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions | Q37096303 |
| | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics | Q37142442 |
| | The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people | Q37172521 |
| | Treatment recommendations for psoriatic arthritis. | Q37284516 |
| | Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases | Q37299387 |
| | Mortality in psoriatic arthritis. | Q37331985 |
| | Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference | Q37457321 |
| | Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease | Q37581067 |
| | How to prevent glucocorticoid-induced osteoporosis | Q37777521 |
| | Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program | Q37778661 |
| | Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity | Q37859676 |
| | Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. | Q39872599 |
| | Which chronic conditions are associated with better or poorer quality of life? | Q40746155 |
| | The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 |
| | Psoriasis causes as much disability as other major medical diseases | Q41686702 |
| | The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year | Q42955715 |
| | Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial | Q44151825 |
| | The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. | Q44416430 |
| | Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study | Q45335424 |
| | Follicular mucinosis: clinical, histologic, and molecular remission with minocycline. | Q45919724 |
| | Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study | Q46297341 |
| | Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis | Q46719337 |
| | Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial | Q48738063 |
| | Development of a preliminary composite disease activity index in psoriatic arthritis | Q48742412 |
| | A randomized trial of etanercept as monotherapy for psoriasis | Q48973610 |
| | Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis | Q49041027 |
| | Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. | Q50882370 |
| | Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. | Q51821980 |
| | Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. | Q52905765 |
| | A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. | Q53218611 |
| | Epidemiology of psoriatic arthritis in the population of the United States. | Q53276933 |
| | The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. | Q53493261 |
| | The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress | Q53644183 |
| | Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. | Q53725487 |
| | Suicidal ideation in psoriasis | Q70588554 |
| | Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis | Q71320042 |
| | Nonsteroidal anti-inflammatory drug gastropathy | Q71523193 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| P304 | page(s) | 588-598 | |
| P577 | publication date | 2011-09-13 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Management of psoriatic arthritis from the view of the dermatologist | |
| P478 | volume | 7 | |